Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.1.74 - deoxycytidine kinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
2',3'-Dideoxynucleoside phosphorylation by deoxycytidine kinase from normal human thymus extracts: activation of potential drugs for AIDS therapy.
Quantitative immunoassay of human deoxycytidine kinase in malignant cells.
Adenocarcinoma
dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
Adenocarcinoma of Lung
Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma.
[Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line]
Arthritis, Rheumatoid
Deoxycytidine kinase promotes the migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients.
Ataxia Telangiectasia
ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.
The Role of Deoxycytidine Kinase (dCK) in Radiation-Induced Cell Death.
Brain Neoplasms
Pyrimidine pathways enzymes in human tumors of brain and associated tissues: potentialities for the therapeutic use of N-(phosphonacetyl-L-aspartate and 1-beta-D-arabinofuranosylcytosine.
Breast Neoplasms
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
Decitabine response in breast cancer requires efficient drug processing and is not limited by multidrug resistance.
Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs.
Deoxycytidine kinase participates in the regulation of radiation-induced autophagy and apoptosis in breast cancer cells.
Drug resistance in hematologic malignancies.
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.
Carcinoma
A novel affinity chromatography method for the co-purification of deoxycytidine kinase and cytidine deaminase.
Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
Clinicopathological significance of deoxycytidine kinase expression in esophageal squamous cell carcinoma.
Enhancement of cytarabine sensitivity in squamous cell carcinoma cell line transfected with deoxycytidine kinase.
Expression of Nucleoside Transporters and Deoxycytidine Kinase Proteins in Muscle Invasive Urothelial Carcinoma of the Bladder: Correlation with Pathological Response to Neoadjuvant Platinum/Gemcitabine Combination Chemotherapy.
Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells.
Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine.
Isolation of deoxycytidine kinase from Ehrlich carcinoma cells by affinity chromatography based on a substrate analog, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-N4-palmitoylcytosine++ +.
Regulation of deoxycytidine kinase activity and inhibition by DFDC.
Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by gamma-irradiation.
Carcinoma, Hepatocellular
Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine.
Phosphorylation of 1-beta-D-arabinofuranosylcytosine by the cell-free extract of rat ascites hepatoma, in relation to the mechanism of natural resistance.
Regulation of deoxycytidine kinase activity and inhibition by DFDC.
Carcinoma, Non-Small-Cell Lung
Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by gamma-irradiation.
[Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]
Carcinoma, Squamous Cell
Enhancement of cytarabine sensitivity in squamous cell carcinoma cell line transfected with deoxycytidine kinase.
Colonic Neoplasms
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
deoxycytidine kinase deficiency
2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.
Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications.
N-Acyl-phosphoramidates as potential novel form of gemcitabine prodrugs.
Preclinical combination therapy with gemcitabine and mechanisms of resistance.
S-adenosylhomocysteine hydrolase inactivation and purine toxicity in cultured human T- and B-lymphoblasts.
Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma.
diacylglycerol kinase (atp) deficiency
Deoxyribonucleoside kinases in mitochondrial DNA depletion.
Drug-Related Side Effects and Adverse Reactions
Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.
Esophageal Squamous Cell Carcinoma
Clinicopathological significance of deoxycytidine kinase expression in esophageal squamous cell carcinoma.
Fowlpox
Fowlpox virus encodes a protein related to human deoxycytidine kinase: further evidence for independent acquisition of genes for enzymes of nucleotide metabolism by different viruses.
Glioma
Adenoviral vector transduction of the human deoxycytidine kinase gene enhances the cytotoxic and radiosensitizing effect of gemcitabine on experimental gliomas.
Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo.
Hashimoto Disease
Expression of genes for certain enzymes of pyrimidine and purine salvage pathway in peripheral blood leukocytes collected from patients with Graves' or Hashimoto's disease.
Hematologic Neoplasms
Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5'-nucleotidase mRNA measurement in cell lines and in patients with leukemia.
[Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine]
Hepatitis
Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues.
Hepatitis B
Molecular basis for the antiviral and anticancer activities of unnatural L-beta-nucleosides.
Hepatitis B, Chronic
The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine.
Hepatitis, Autoimmune
18F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis.
Herpes Simplex
Association of thymidylate kinase activity with pyrimidine deoxyribonucleoside kinase induced by herpes simplex virus.
Comparative Analysis of T Cell Imaging with Human Nuclear Reporter Genes.
Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma.
Deoxycytidine kinase from rabbit kidney cells infected with herpes simplex virus type 1 or 2.
Deoxypyrimidine kinases of herpes simplex viruses types 1 and 2: comparison of serological and structural properties.
Deoxyribonucleoside triphosphate pools in herpes simplex type 1 infected cells.
Herpes simplex virus specified deoxypyrimidine kinase and the uptake of exogenous nucleosides by infected cells.
Molecular basis for the antiviral and anticancer activities of unnatural L-beta-nucleosides.
Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro.
[Deoxythymidine kinase and deoxycytidine kinase induced by herpes simplex virus type I and type II - a difference between the 2 types]
HIV Infections
Thymidine kinase and deoxycytidine kinase in HIV-infected children.
Infections
Deoxyribonucleoside triphosphate pools in herpes simplex type 1 infected cells.
Enhancement of deoxyguanosine kinase activity in human lung fibroblast cells infected with human cytomegalovirus.
Leukemia
A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells.
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative.
Changes in the activities of cytidine deaminase during differentiation of HL60 cells induced by 1,25 dihydroxy D3.
Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia.
Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay.
Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia.
Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients.
Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity.
Increased Deoxycytidine Kinase mRNA Level After Treatment with Interleukin-3.
Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma.
Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model.
Purification and characterization of deoxycytidine kinase from acute myeloid leukemia cell mitochondria.
Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5'-nucleotidase mRNA measurement in cell lines and in patients with leukemia.
Regulation of deoxycytidine kinase by deoxycytidine and deoxycytidine 5' triphosphate in whole leukemia and tumor cells.
Resistance to mitochondrial- and Fas-mediated apoptosis in human leukemic cells with acquired resistance to 9-beta-D-arabinofuranosylguanosine.
Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma.
[Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine]
Leukemia L1210
Differential affinities of pyrimidine nucleoside analogues for deoxythymidine and deoxycytidine kinase determine their incorporation into murine leukemia L1210 cells.
Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
Leukemia, Erythroblastic, Acute
Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity.
Leukemia, Lymphocytic, Chronic, B-Cell
Activation of deoxycytidine kinase by UV-C-irradiation in chronic lymphocytic leukemia B-lymphocytes.
Deoxynucleoside anabolic enzyme levels in acute myelocytic leukemia and chronic lymphocytic leukemia cells.
Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL).
The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia.
[Correlation of deoxycytidine kinase gene expression with fludarabine resistance in patients with chronic lymphocytic leukemia]
Leukemia, Lymphoid
Metabolism and ribonucleotide reductase inhibition of (E)-2'-deoxy-2'-(fluoromethylene)cytidine, MDL 101,731, in human cervical carcinoma HeLa S3 cells.
Leukemia, Myeloid
Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients.
Leukemia, Myeloid, Acute
Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML).
Cloning of the Dck gene encoding rat deoxycytidine kinase.
Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.
Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia.
Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines.
Deoxynucleoside anabolic enzyme levels in acute myelocytic leukemia and chronic lymphocytic leukemia cells.
Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase II? as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin.
High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia.
Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients.
In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Potential mechanisms of resistance to cytarabine in AML patients.
Purification and characterization of deoxycytidine kinase from acute myeloid leukemia cell mitochondria.
Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.
Role of USF1 in the differential expression of the human deoxycytidine kinase gene in acute myeloid leukemia.
Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside.
The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia.
Liver Neoplasms
DCK is an Unfavorable Prognostic Biomarker and Correlated With Immune Infiltrates in Liver Cancer.
Lung Diseases
Hypoxia-induced deoxycytidine kinase expression contributes to apoptosis in chronic lung disease.
Lung Neoplasms
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells.
Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein.
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin.
Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane.
Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by gamma-irradiation.
[Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]
Lymphoma
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
Lymphoma, Follicular
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene.
Lymphoma, Large B-Cell, Diffuse
Characterization of an adenosine deaminase-deficient human histiocytic lymphoma cell line (DHL-9) and selection of mutants deficient in adenosir kinase and deoxycytidine kinase.
Lymphoma, Mantle-Cell
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Lymphoma, Non-Hodgkin
Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.
Multiple Sclerosis
Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status.
Myelodysplastic Syndromes
Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome.
Neoplasm Metastasis
Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver.
Neoplasms
2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.
Activation of deoxycytidine kinase by gamma-irradiation and inactivation by hyperosmotic shock in human lymphocytes.
Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes.
Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells.
Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues.
Analysis of DNA methylation of the 5' region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)-resistant cells.
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
Antitumor activity of sugar-modified cytosine nucleosides.
Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.
Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer.
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Cytostatic and cytotoxic effects of (E)-2'-deoxy-2'-(fluoromethylene)-cytidine on a solid tumor and a leukemia cell line.
Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein.
DCK is an Unfavorable Prognostic Biomarker and Correlated With Immune Infiltrates in Liver Cancer.
Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma.
Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.
Enhancement of cytarabine sensitivity in squamous cell carcinoma cell line transfected with deoxycytidine kinase.
Enzyme-Driven Chemo-and Radiation-Therapy with 12 Pyrimidine Nucleoside Analogs Not Yet in the Clinic.
Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues.
Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver.
Five-chlorodeoxycytidine, a tumor-selective enzyme-driven radiosensitizer, effectively controls five advanced human tumors in nude mice.
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Genomic structure and chromosomal localization of the human deoxycytidine kinase gene.
Homogeneous assay for real-time and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities.
Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.
Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours.
Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity.
In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2'-deoxycytidine.
Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine.
Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.
Kinase and deaminase activity in a variety of subcutaneous mouse tumors.
Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma.
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.
Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3?) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies.
Molecular Imaging of Deoxycytidine Kinase Activity Using Deoxycytidine-Enhanced CEST MRI.
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.
Numerical analysis of apparent decitabine uptake in HCT116 cells: Incorporation of a bidirectional first-order kinetic parameter for ENT1 transport and Michaelis-Menten parameters for subsequent phosphorylation.
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.
Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase.
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Pyrimidine pathways enzymes in human tumors of brain and associated tissues: potentialities for the therapeutic use of N-(phosphonacetyl-L-aspartate and 1-beta-D-arabinofuranosylcytosine.
Quantitative immunoassay of human deoxycytidine kinase in malignant cells.
Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine.
Regulation of deoxycytidine kinase activity and inhibition by DFDC.
Regulation of deoxycytidine kinase by deoxycytidine and deoxycytidine 5' triphosphate in whole leukemia and tumor cells.
Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
Requirement for deoxycytidine kinase in T and B lymphocyte development.
Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
Retrovolution: HIV-Driven Evolution of Cellular Genes and Improvement of Anticancer Drug Activation.
Role of deoxycytidine kinase in the inhibitory activity of 5-substituted 2'-deoxycytidines and cytosine arabinosides on tumor cell growth.
Small Molecular Gemcitabine Prodrugs for Cancer Therapy.
Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.
Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-?-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-?-L-arabinofuranosyl)-5-methylcytosine PET.
Structure of human dCK suggests strategies to improve anticancer and antiviral therapy.
Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Transcriptional regulation of the mouse deoxycytidine kinase: identification and functional analysis of nuclear protein binding sites at the proximal promoter.
Transduction of the human deoxycytidine kinase gene in rodent tumor cells induces in vivo growth retardation in syngeneic hosts.
Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response.
Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.
[Acquisition of resistance associated with impairment of metabolic activation of anticancer drugs]
[Nucleoside kinases and new types of antitumor nucleosides]
Neuroblastoma
Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma.
Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma.
Neurofibrosarcoma
A study of the influence of newly synthesized acyclonucleosides and 1,2,3,4-tetrahydroisoquinoline derivatives on deoxythymidine and deoxycytidine kinase activities in human neurofibrosarcoma and ovarian cancer.
Ovarian Neoplasms
A study of the influence of newly synthesized acyclonucleosides and 1,2,3,4-tetrahydroisoquinoline derivatives on deoxythymidine and deoxycytidine kinase activities in human neurofibrosarcoma and ovarian cancer.
Biological activity of 1-deazapurine nucleosides: role of deoxycytidine kinase?
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
Pancreatic Neoplasms
All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.
Attenuation of Phosphorylation by Deoxycytidine Kinase is Key to Acquired Gemcitabine Resistance in a Pancreatic Cancer Cell Line: Targeted Proteomic and Metabolomic Analyses in PK9 Cells.
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines.
Expression of Nucleoside Transporters and Deoxycytidine Kinase Proteins in Muscle Invasive Urothelial Carcinoma of the Bladder: Correlation with Pathological Response to Neoadjuvant Platinum/Gemcitabine Combination Chemotherapy.
HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
New applications of gemcitabine and future directions in the management of pancreatic cancer.
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia.
Pulmonary Fibrosis
Hypoxia-induced deoxycytidine kinase contributes to epithelial proliferation in pulmonary fibrosis.
Sarcoma
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.
Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine.
Thyroid Cancer, Papillary
Increased expression of mRNA specific for thymidine kinase, deoxycytidine kinase or thymidine phosphorylase in human papillary thyroid carcinoma.
Thyroid Diseases
Expression of genes for certain enzymes of pyrimidine and purine salvage pathway in peripheral blood leukocytes collected from patients with Graves' or Hashimoto's disease.
Urinary Bladder Neoplasms
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Uterine Cervical Neoplasms
Effects of DCK knockdown on proliferation, apoptosis and tumorigenicity in vivo of cervical cancer HeLa cells.
Virus Diseases
Requirement for deoxycytidine kinase in T and B lymphocyte development.